Galen (chemicals) Limited

Warner Chilcott Company, LLC

Allergan Pharmaceuticals International Limited

Warner Chilcott, LLC

Claire Gilligan

Clare Passmore

Brendan Muldoon

James William McIlroy

James Keown

John Alexander King

William Paul Armstrong

Colin Lorimer

James William Mcilroy

The present invention relates to a process for the preparation of an intravaginal matrix drug delivery device. The process comprises the steps of combining at least one therapeutic agent in a therapeutically effective amount with at least one biocompatible elastomeric polymer to form a mix; curing said mix in a mold having a shape of said intravaginal drug delivery device, to form a polymer matrix; and maturing said polymer matrix to form the intravaginal drug delivery device. The maturing step alters the release rate characteristics of a device prepared in accordance with the process of the invention.

Intravaginal matrix drug delivery devices

The present invention is a prodrug derivative of ethinyl estradiol according to Formula I: 

Derivative prodrugs of ethinyl estradiol

The invention concerns a topical composition comprising an emulsion of at least one discontinuous phase in a continuous phase, the or each discontinuous phase including a eutectic mixture of first and second pharmaceutically acceptable components which are both pharmacologically active agents and the continuous phase being provided by a pharmaceutically acceptable carrier, the eutectic mixture having a melting point below 40&#xb0; C. The topical composition may additionally comprise, in the eutectic mixture, a third or fourth pharmaceutically acceptable component.

Topical compositions

This invention relates to an intravaginal shell or core drug delivery device suitable for administration to female humans or animals comprises testosterone or a testosterone precursor in a polymer matrix, surrounded by a sheath, and is capable of releasing the testosterone or testosterone precursor in a substantially zero-order pattern on a daily basis for at least three weeks. The device is intended to restore circulating testosterone levels to the normal physiol, range or to induce supratherapeutic testosterone levels.

Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors

Growing community of inventors

Belfast, United Kingdom

Claire Gilligan